HRMY Harmony Biosciences Holdings, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Neuroscience-focused biopharma developing innovative treatments for rare neurological diseases emphasizing sleep/wake disorders, rare epilepsy, and neurobehavioral conditions
• • New products and expansions: Acquired orexin 2 receptor agonist BP1.15205 (preclinical), launched Phase 3 trials for next-gen pitolisant formulations (GR and HD), expanded rare epilepsy pipeline via Epygenix acquisition with EPX-100 and EPX-200
• • Strategic shift: Diversified beyond pitolisant with Zynerba acquisition (ZYN002 cannabidiol gel), entry into orexin science, and cell replacement therapy collaboration with CiRC Biosciences
• • Quantitative highlight: WAKIX net revenue $868.5M in 2025 with ~8,500 average patients on therapy; filed NDA for Pitolisant GR targeting Q1 2027 FDA review
• • Noteworthy: FDA approvals expanded WAKIX pediatric indications for EDS (2024) and cataplexy (2026); Phase 3 negative RECONNECT trial led to phasing out ZYN002 in Fragile X syndrome

Risk Factors

• • Regulatory risk: FDA post-marketing requirements and commitments for WAKIX, including recent approvals for pediatric narcolepsy in June 2024 and February 2026
• • Geopolitical/macroeconomic risk: reliance on third-party manufacturing with sole-source suppliers and manufacturers, exposing supply chain to disruption risks
• • Operational risk: dependence on Bioprojet license for core pitolisant IP, with risk of termination restricting commercialization rights in the U.S.
• • Competitive risk: WAKIX faces competition from modafinil, which showed non-inferiority, potentially limiting physician prescribing and market acceptance
• • Financial risk: dependence on WAKIX sales for substantially all revenue, with failure to grow sales potentially causing loss of profitability and need for additional financing

Management Discussion & Analysis

• • Revenue $868.5M, up 21.5% YoY (+$153.7M) driven by 18.3% volume growth and 7.0% price increase, offset by 3.6% higher rebates
• • Gross margin 77.2% (cost of sales 22.8%) vs 78.1% (cost of sales 21.9%) in prior year, impacted by higher royalty tier
• • R&D expenses $189.6M, up 30.0% (+$43.8M) led by EPX-100 (+$27.2M), ZYN002 (+$8.0M), and Pitolisant GR/HD (+$11.9M); offset by $7.7M decrease for Pitolisant IH
• • Net income $158.7M, up from $145.5M; Operating income $208.5M vs $190.8M prior year
• • Capital allocation: no specific buybacks or dividends disclosed; $0.5M rent/consulting fees; increased investments in clinical trials and manufacturing; forward-looking focus on advancing multiple Phase 3 programs and pursuing pediatric exclusivity with potential PDUFA dates in 2027-2028

What are the latest HRMY SEC filings in 2026?

Harmony Biosciences Holdings, Inc. (HRMY) has filed a 10-K annual report on February 24, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did HRMY file its most recent 10-K annual report?

Harmony Biosciences Holdings, Inc. (HRMY) filed its most recent 10-K annual report on February 24, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view HRMY 10-Q quarterly reports?

Harmony Biosciences Holdings, Inc. (HRMY)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every HRMY 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has HRMY filed recently?

Harmony Biosciences Holdings, Inc. (HRMY)'s most recent 8-K was filed on August 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find HRMY insider trading activity (Form 4)?

SignalX aggregates every HRMY Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does HRMY file with the SEC?

Harmony Biosciences Holdings, Inc. (HRMY) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new HRMY filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Harmony Biosciences Holdings, Inc. (HRMY).

What is HRMY's SEC CIK number?

Harmony Biosciences Holdings, Inc. (HRMY)'s SEC CIK (Central Index Key) number is 1802665. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1802665 to look up all HRMY filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find HRMY return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Harmony Biosciences Holdings, Inc. (HRMY) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.